Skip to main content

Advertisement

SpringerLink
Log in

Ubiquitinomics revealed disease- and stage-specific patterns relevant for the 3PM approach in human sigmoid colon cancers

  • Research
  • Published:
EPMA Journal Aims and scope Submit manuscript

Abstract

Objective

The patients with sigmoid colorectal cancer commonly show high mortality and poor prognosis. Increasing evidence has demonstrated that the ubiquitinated proteins and ubiquitination-mediated molecular pathways influence the growth and aggressiveness of colorectal cancer. It emphasizes the scientific merits of quantitative ubiquitinomics in human sigmoid colon cancer. We hypothesize that the ubiquitinome and ubiquitination-mediated pathway networks significantly differ in sigmoid colon cancers compared to controls, which offers the promise for in-depth insight into molecular mechanisms, discovery of effective therapeutic targets, and construction of reliable biomarkers in the framework of predictive, preventive, and personalized medicine (PPPM; 3P medicine).

Methods

The first ubiquitinome analysis was performed with anti-K-ε-GG antibody beads (PTMScan ubiquitin remnant motif [K-ε-GG])-based label-free quantitative proteomics and bioinformatics to identify and quantify ubiquitination profiling between sigmoid colon cancer tissues and para-carcinoma tissues. A total of 100 human sigmoid colon cancer samples that included complete clinical information and the corresponding gene expression data were obtained from The Cancer Genome Atlas (TCGA). Ubiquitination was the main way of protein degradation; the relationships between differentially ubiquitinated proteins (DUPs) and their differently expressed genes (DEGs) and between DUPs and their differentially expressed proteins (DEPs) were analyzed between cancer tissues and control tissues. The overall survival of those DUPs was obtained with Kaplan-Meier method.

Results

A total of 1249 ubiquitinated sites within 608 DUPs were identified in human sigmoid colon cancer tissues. KEGG pathway network analysis of these DUPs revealed 35 statistically significant signaling pathways, such as salmonella infection, glycolysis/gluconeogenesis, and ferroptosis. Gene Ontology (GO) analysis of 608 DUPs revealed that protein ubiquitination was involved in 98 biological processes, 64 cellular components, 51 molecule functions, and 26 immune system processes. Protein-protein interaction (PPI) network of 608 DUPs revealed multiple high-combined scores and co-expressed DUPs. The relationship analysis between DUPs and their DEGs found 4 types of relationship models, including DUP-up (increased ubiquitination level) and DEG-up (increased gene expression), DUP-up and DEG-down (decreased gene expression), DUP-down (decreased ubiquitination level) and DEG-up, and DUP-down and DEG-down. The relationship analysis between DUPs and their DEPs found 4 types of relationship models, including DUP-up and DEP-up (increased protein expression), DUP-up and DEP-down (decreased protein expression), DUP-down and DEP-up, and DUP-down and DEP-down. Survival analysis found 46 overall survival-related DUPs in sigmoid colon cancer, and the drug sensitivity of overall survival-related DUPs were identified.

Conclusion

The study provided the first differentially ubiquitinated proteomic profiling, ubiquitination-involved signaling pathway network changes, and the relationship models between protein ubiquitination and its gene expression and between protein ubiquitination and its protein expression, in human sigmoid colon cancer. It offers the promise for deep insights into molecular mechanisms of sigmoid colon cancer, and discovery of effective therapeutic targets and biomarkers for patient stratification, predictive diagnosis, prognostic assessment, and personalized treatment in the context of 3P medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data availability

All data and materials are provided in this article and supplemental materials, which can be available publicly.

Code availability

All protein and gene accession codes can be available in the Swiss-Prot and GenBank databases.

Abbreviations

AvrA :

virulence factor

ABIN-1 :

ubiquitin-binding protein

ATP :

adenosine triphosphate

BP :

biological process

DEG :

differently expressed genes

DUB :

deubiquitinases

DUP :

differentially ubiquitinated proteins

GO :

Gene Ontology

ISP :

immune system process

KEGG :

Kyoto Encyclopedia of Genes and Genomes

K-ε-GG :

ubiquitinated lysine

LC :

liquid chromatography

MLKL :

mixed lineage kinase domain-like

MS/MS :

tandem mass spectrometry

OS :

overall survival

PHGDH :

phosphoglycerate dehydrogenase

PPI :

protein-protein interaction

PPPM :

predictive, preventive, and personalized medicine

PTM :

post-translational modifications

RIPK3 :

receptor-interacting serine-threonine kinase 3

ROS :

reactive oxygen species

TCGA :

The Cancer Genome Atlas

TH1 :

CD4+T helper 1 cells

TH-17 :

T helper interleukin 17 producing

Treg :

T regulatory cells

UBD :

ubiquitin protein-binding domains

UPS :

ubiquitin proteasome system

References

  1. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418–32. https://doi.org/10.1053/j.gastro.2019.06.043.

    Article  CAS  PubMed  Google Scholar 

  2. Kobayashi R, Ogura A, Kawai S, Takagi K, Kawai K, Maeda T, et al. Laparoscopic surgery for sigmoid colon cancer with complicated communication between the superior and inferior mesenteric arteries. Asian J Endosc Surg. 2021;14:267–70. https://doi.org/10.1111/ases.12844.

    Article  PubMed  Google Scholar 

  3. Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, et al. Clinicopathological and molecular differences in colorectal cancer according to location. Int J Biol Markers. 2019;34:47–53. https://doi.org/10.1177/1724600818807164.

    Article  CAS  PubMed  Google Scholar 

  4. de Boer NL, Rovers K, Burger JWA, Madsen EVE, Brandt-Kerkhof ARM, Kok NFM, et al. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer. Cancer Med. 2020;9:5851–9. https://doi.org/10.1002/cam4.3243.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vogelsang RP, Gögenur M, Dencker D, Bjørn Bennedsen AL, Levin Pedersen D, Gögenur I. Routine CT evaluation of central vascular ligation in patients undergoing complete mesocolic excision for sigmoid colon cancer. Colorectal Dis. 2021;23:2030–40. https://doi.org/10.1111/codi.15723.

    Article  PubMed  Google Scholar 

  6. Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: regulators of neurodegenerative proteinopathies. Ageing Res Rev. 2021;68:101336. https://doi.org/10.1016/j.arr.2021.101336.

    Article  CAS  PubMed  Google Scholar 

  7. Lu M, Chen W, Zhuang W, Zhan X. Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas. Epma j. 2020;11:73–94. https://doi.org/10.1007/s13167-019-00197-8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gulei D, Drula R, Ghiaur G, Buzoianu AD, Kravtsova-Ivantsiv Y, Tomuleasa C, et al. The tumor suppressor functions of ubiquitin ligase KPC1: from cell cycle control to NF-κB regulator. Cancer Res. 2023;83(11):1762–7. https://doi.org/10.1158/0008-5472.Can-22-3739.

    Article  CAS  PubMed  Google Scholar 

  9. Trulsson F, Akimov V, Robu M, van Overbeek N, Berrocal DAP, Shah RG, et al. Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates. Nat Commun. 2022;13:2736. https://doi.org/10.1038/s41467-022-30376-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Stekel Z, Sheng Y, Zhang W. The multifaceted role of the ubiquitin proteasome system in pathogenesis and diseases. Biomolecules. 2022;12:925. https://doi.org/10.3390/biom12070925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43:1144–61. https://doi.org/10.1007/s12272-020-01281-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Singh SR, Meyer-Jens M, Alizoti E, Bacon WC, Davis G, Osinska H, et al. A high-throughput screening identifies ZNF418 as a novel regulator of the ubiquitin-proteasome system and autophagy-lysosomal pathway. Autophagy. 2021;17:3124–39. https://doi.org/10.1080/15548627.2020.1856493.

    Article  CAS  PubMed  Google Scholar 

  13. Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE, Vucic D. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28:591–605. https://doi.org/10.1038/s41418-020-00708-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tu Y, Xu L, Xu J, Bao Z, Tian W, Ye Y, et al. Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-β signaling. Oncogene. 2022;41:2597–608. https://doi.org/10.1038/s41388-022-02275-0.

    Article  CAS  PubMed  Google Scholar 

  15. Zhu G, Herlyn M, Yang X. TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nat Cell Biol. 2021;23:978–91. https://doi.org/10.1038/s41556-021-00732-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kodroń A, Mussulini BH, Pilecka I, Chacińska A. The ubiquitin-proteasome system and its crosstalk with mitochondria as therapeutic targets in medicine. Pharmacol Res. 2021;163:105248. https://doi.org/10.1016/j.phrs.2020.105248.

    Article  CAS  PubMed  Google Scholar 

  17. Aliabadi F, Sohrabi B, Mostafavi E, Pazoki-Toroudi H, Webster TJ. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021;11:200390. https://doi.org/10.1098/rsob.200390.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhan X, Li J, Guo Y, Golubnitschaja O. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. Epma j. 2021;12:449–75. https://doi.org/10.1007/s13167-021-00265-y.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Liu D, Li J, Li N, Lu M, Wen S, Zhan X. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas. EPMA J. 2020;11:419–67. https://doi.org/10.1007/s13167-020-00215-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 2018;9:77–102. https://doi.org/10.1007/s13167-018-0128-8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Zhang Z, He G, Lv Y, Liu Y, Niu Z, Feng Q, et al. HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer. Cell Death Dis. 2022;13:74. https://doi.org/10.1038/s41419-022-04511-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fang L, Ford-Roshon D, Russo M, O'Brien C, Xiong X, Gurjao C, et al. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. Nat Commun. 2022;13:3181. https://doi.org/10.1038/s41467-022-30794-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Agarwal E, Goldman AR, Tang HY, Kossenkov AV, Ghosh JC, Languino LR, et al. A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression. Sci Adv. 2021;7:eabg7287. https://doi.org/10.1126/sciadv.abg7287.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang Y, Chen C, Yu T, Chen T. Proteomic analysis of protein ubiquitination events in human primary and metastatic colon adenocarcinoma tissues. Front Oncol. 2020;10:1684. https://doi.org/10.3389/fonc.2020.01684.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wang T, Jin C, Yang P, Chen Z, Ji J, Sun Q, et al. UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3. Oncogene. 2023;42:651–64. https://doi.org/10.1038/s41388-022-02581-7.

    Article  CAS  PubMed  Google Scholar 

  26. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem. 2006;281:17751–7. https://doi.org/10.1074/jbc.M600831200.

    Article  CAS  PubMed  Google Scholar 

  27. Zhou R, Chen J, Xu Y, Ye Y, Zhong G, Chen T, et al. PRPF19 facilitates colorectal cancer liver metastasis through activation of the Src-YAP1 pathway via K63-linked ubiquitination of MYL9. Cell Death Dis. 2023;14:258. https://doi.org/10.1038/s41419-023-05776-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wang W, Zhou Z, Xiang L, Lv M, Ni T, Deng J, et al. CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis. Int J Biol Sci. 2020;16:719–29. https://doi.org/10.7150/ijbs.41125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Duijster JW, Hansen JV, Franz E, Neefjes JJC, Frisch M, Mughini-Gras L, et al. Association between Salmonella infection and colon cancer: a nationwide registry-based cohort study. Epidemiol Infect. 2021;149:e56. https://doi.org/10.1017/s0950268821000285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dougherty MW, Jobin C. Intestinal bacteria and colorectal cancer: etiology and treatment. Gut Microbes. 2023;15:2185028. https://doi.org/10.1080/19490976.2023.2185028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Liu K, Yang X, Zeng M, Yuan Y, Sun J, He P, et al. The role of fecal Fusobacterium nucleatum and pks(+) Escherichia coli as early diagnostic markers of colorectal cancer. Dis Markers. 2021;2021:1171239. https://doi.org/10.1155/2021/1171239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022;28:4053–60. https://doi.org/10.3748/wjg.v28.i30.4053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang XM, Yang C, Zhao Y, Xu ZG, Yang W, Wang P, et al. The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer. Nat Cancer. 2020;1:811–25. https://doi.org/10.1038/s43018-020-0089-4.

    Article  CAS  PubMed  Google Scholar 

  34. Li N, Li H, Wang Y, Cao L, Zhan X. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. Epma j. 2020;11:661–94. https://doi.org/10.1007/s13167-020-00224-z.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Li N, Zhan X. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. Epma j. 2020;11:289–309. https://doi.org/10.1007/s13167-020-00209-y.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Li N, Zhan X. Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine. Epma j. 2021;12:605–27. https://doi.org/10.1007/s13167-021-00256-z.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Zhang Y, Yu H, Zhang J, Gao H, Wang S, Li S, et al. Cul4A-DDB1-mediated monoubiquitination of phosphoglycerate dehydrogenase promotes colorectal cancer metastasis via increased S-adenosylmethionine. J Clin Invest. 2021;131:21. https://doi.org/10.1172/jci146187.

    Article  CAS  Google Scholar 

  38. Zou S, Qin B, Yang Z, Wang W, Zhang J, Zhang Y, et al. CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer. Cancer Res. 2023;83:414–27. https://doi.org/10.1158/0008-5472.Can-22-2145.

    Article  CAS  PubMed  Google Scholar 

  39. Chaudhary N, Choudhary BS, Shah SG, Khapare N, Dwivedi N, Gaikwad A, et al. Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer. Int J Cancer. 2021;149:1495–511. https://doi.org/10.1002/ijc.33711.

    Article  CAS  PubMed  Google Scholar 

  40. Chen C, Yang Y, Guo Y, He J, Chen Z, Qiu S, et al. CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer. Cell Death Dis. 2023;14:271. https://doi.org/10.1038/s41419-023-05803-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Han Y, Gao X, Wu N, Jin Y, Zhou H, Wang W, et al. Long noncoding RNA LINC00239 inhibits ferroptosis in colorectal cancer by binding to Keap1 to stabilize Nrf2. Cell Death Dis. 2022;13:742. https://doi.org/10.1038/s41419-022-05192-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cai J, Hu D, Sakya J, Sun T, Wang D, Wang L, et al. ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer. Cell Death Dis. 2021;12:140. https://doi.org/10.1038/s41419-021-03427-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wu Q, Huang Q, Jiang Y, Sun F, Liang B, Wang J, et al. Remodeling chondroitin-6-sulfate-mediated immune exclusion enhances anti-PD-1 response in colorectal cancer with microsatellite stability. Cancer Immunol Res. 2022;10:182–99. https://doi.org/10.1158/2326-6066.Cir-21-0124.

    Article  CAS  PubMed  Google Scholar 

  44. Laske K, Shebzukhov YV, Grosse-Hovest L, Kuprash DV, Khlgatian SV, Koroleva EP, et al. Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunity. Cancer Immunol Res. 2013;1:190–200. https://doi.org/10.1158/2326-6066.Cir-13-0079.

    Article  CAS  PubMed  Google Scholar 

  45. Osman A, Yan B, Li Y, Pavelko KD, Quandt J, Saadalla A, et al. TCF-1 controls T(reg) cell functions that regulate inflammation, CD8(+) T cell cytotoxicity and severity of colon cancer. Nat Immunol. 2021;22:1152–62. https://doi.org/10.1038/s41590-021-00987-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13:5644. https://doi.org/10.1038/s41467-022-33285-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kit OI, Vodolazhsky DI, Kutilin DS, Enin YS, Gevorkyan YA, Zolotukhin PV, Boumber Y, Kharin LV, Panina SB. A proteomics analysis reveals 9 up-regulated proteins associated with altered cell signaling in colon cancer patients. Protein J. 2017;36:513–22. https://doi.org/10.1007/s10930-017-9746-6.

    Article  CAS  PubMed  Google Scholar 

  48. Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, et al. Clinical Proteomic Tumor Analysis Consortium. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177(4):1035–1049.e19. https://doi.org/10.1016/j.cell.2019.03.030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Buttacavoli M, Albanese NN, Roz E, Pucci-Minafra I, Feo S, Cancemi P. Proteomic profiling of colon cancer tissues: discovery of new candidate biomarkers. Int J Mol Sci. 2020;21(9):3096. https://doi.org/10.3390/ijms21093096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Roblick UJ, Hirschberg D, Habermann JK, Palmberg C, Becker S, Krüger S, Gustafsson M, Bruch HP, Franzén B, Ried T, Bergmann T, Auer G, Jörnvall H. Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci. 2004;61(10):1246–55. https://doi.org/10.1007/s00018-004-4049-4.

    Article  CAS  PubMed  Google Scholar 

  51. Zhou J, Xu Y, Lin S, Guo Y, Deng W, Zhang Y, Guo A, Xue Y. iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations. Nucleic Acids Res. 2018;46(D1):D447–53. https://doi.org/10.1093/nar/gkx1041.

    Article  CAS  PubMed  Google Scholar 

  52. Chang SC, Zhang BX, Ding JL. E2-E3 ubiquitin enzyme pairing — partnership in provoking or mitigating cancers. Biochim Biophys Acta Rev Cancer. 2022;1877(2):188679. https://doi.org/10.1016/j.bbcan.2022.188679.

    Article  CAS  PubMed  Google Scholar 

  53. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 2013;73(1):225–34. https://doi.org/10.1158/0008-5472.CAN-12-1729.

    Article  CAS  PubMed  Google Scholar 

  54. Xu H, Zhou S, Xia H, Yu H, Tang Q, Bi F. MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. Cell Death Differ. 2019;26(11):2400–15. https://doi.org/10.1038/s41418-019-0309-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Tong G, Cheng B, Wu X, He L, Lv G, Wang S. circHIPK2 has a potentially important clinical significance in colorectal cancer progression via HSP90 ubiquitination by miR485-5p. Crit Rev Eukaryot Gene Expr. 2022;32(8):33–42. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2022042925.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge The Cancer Genome Atlas (TCGA) project organizers as well as all study participants for providing the publicly available TCGA RNA-seq data and clinical data.

Funding

This work was supported by the Shandong Provincial Taishan Scholar Engineering Project Special Funds (to X. Z.), SCIBP-Supported Projects (No. SCIBP2021080005), the Shandong Provincial Natural Science Foundation (ZR2021MH156, ZR2022QH112, ZR2020LZL012), the Shandong First Medical University Talent Introduction Funds (to X. Z.), the Shandong First Medical University High-level Scientific Research Achievement Cultivation Funding Program (to X. Z.), Shandong First Medical University Undergraduate Innovation Research Program (Project No. 2022104391511), China National Nature Scientific Funds (82203592), CSCO-CSPC Cancer Research Fund Project, and the Beijing Science and Technology Innovation Medical Development Foundation (No. KC2021-JX-0186-138).

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China

    Hua Yang & Lei Zhou

  2. Medical Science and Technology Innovation Center, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, Shandong, 250117, People’s Republic of China

    Na Li, Wenshuang Jia, Ruofei Chen, Junwen Su, Lamei Yang, Xiaoxia Gong & Xianquan Zhan

  3. Department of Gynecological Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, People’s Republic of China

    Liang Chen

  4. Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China

    Yuanchen Zhou & Jixiang Liu

Authors
  1. Hua Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuanchen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jixiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenshuang Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruofei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junwen Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lamei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiaoxia Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xianquan Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H. Y., N. L., and L. C. analyzed the data, prepared the figures and tables, and designed and wrote the manuscript. W. J., and L. Z. collected the clinical tissue samples, sample diagnosis, and clinical explanation. Y. Z., J. L., R. C., J. S., L. Y., and X. G. participated in the partial data analysis and experiments. X. Z. conceived the concept; obtained the ubiquitinomics original data; supervised the results; designed, wrote, and critically revised manuscript; and was responsible for its financial supports and the corresponding works. All authors approved the final manuscript.

Corresponding author

Correspondence to Xianquan Zhan.

Ethics declarations

Ethical approval

All the patients were informed about the purposes of the study and consequently have signed their “consent of the patient.” All investigations conformed to the principles outlined in the Declaration of Helsinki and were performed with permission by Medical Ethics Committee of Shandong First Medical University, and Clinical Medical Research Ethics Committee of China-Japan Friendship Hospital, China.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary figure 1.

The significant signaling pathways of differentially ubiquitinated proteins in sigmoid cancer (PPTX 2470 kb)

Supplementary figure 2.

The overall survival analysis of differentially ubiquitinated proteins in sigmoid cancer (DOCX 1395 kb)

Supplementary Table 1:

Differentially ubiquitinated proteins in sigmoid cancer identified with quantitative ubiquitinomics. K* = ubiquitinated lysine residue (+114.04). M# = oxidated Met residue (+15.99). C# = Carbamidomethylated Cystine residue (+57.02). (+42.01) means protein N-terminal acetylation. Ratio (T/N) = Ratio (tumor/nornal control). Red = increased ubiquitination level. Green = Descreased ubiquitination level. (XLSX 196 kb)

Supplementary Table 2:

The significant pathways of differentially ubiquitinated proteins in sigmoid colon cancer. (XLSX 19 kb)

Supplementary Table 3:

The Biological Process analysis of differentially ubiquitinated proteins in sigmoid cancer. (XLS 189 kb)

Supplementary Table 4:

TheCellularComponent analysis of differentially ubiquitinated proteins in sigmoid cancer. (XLS 137 kb)

Supplementary Table 5:

The MolecularFunction analysis of differentially ubiquitinated proteins in sigmoid cancer. (XLS 106 kb)

Supplementary Table 6:

The Immune System Process analysis of differentially ubiquitinated proteins in sigmoid cancer. (XLS 70 kb)

Supplementary Table 7:

The protein and protein interaction network of the differentially ubiquitinated proteins in sigmoid cancer. (XLSX 29 kb)

Supplementary Table 8:

Clinical characteristic and corresponding gene expression of sigmoid colon cancer based on TCGA database. (XLSX 504 kb)

Supplementary Table 9:

Differentially expressed genes between cancer and normal tissues based on TCGA database according to the differentially ubiquitinated proteins in sigmoid cancer. (XLSX 17 kb)

Supplementary Table 10.

Differentially expressed proteins (DEPs) identified in colorectal cancers compared to controls*. (XLSX 24 kb)

Supplementary Table 11:

The overall survival of the differentially ubiquitinated proteins in sigmoid cancer. (XLSX 34 kb)

Supplementary Table 12:

The drug sensitivity of the identified differentially ubiquitinated proteins in sigmoid cancer. (XLSX 15 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, H., Li, N., Chen, L. et al. Ubiquitinomics revealed disease- and stage-specific patterns relevant for the 3PM approach in human sigmoid colon cancers. EPMA Journal 14, 503–525 (2023). https://doi.org/10.1007/s13167-023-00328-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13167-023-00328-2

Keywords

Search

Navigation